All Episodes

Modulari-T Biosciences is a Montreal-based biotech working on what may be one of the most significant advances in cell therapy in decades. The team has built the first second generation in vivo CAR-T system, one designed to work with the immune system rather than against it, and has already proven the technology across nearly twenty different target types, including cancers that earlier generations of CAR-T simply could not reach. In this episode, Jim Wilson speaks with CEO Tanya Borsuk about a company she never expected to join. After years at Celgene, which became Bristol-Myers Squibb, watching CAR-T hit its limits, Tanya swore she would never work in the field again. Then she saw Modulari-T's data. She explains what makes the technology different, why toxicity and accessibility have long held cell therapy back, and how this Canadian science could open the door to treating not just cancer but autoimmune, inflammatory, and neurological diseases. Tanya also reflects on the realities of building a young biotech in a difficult market, and why she believes the most important lesson any entrepreneur can learn is to not be afraid to fail.

Based in Calgary, Alberta, Providence Therapeutics is a Canadian mRNA company focused on personalized cancer vaccines. During the pandemic, Brad Sorenson and his team developed a COVID vaccine that went head to head against Pfizer in clinical trials and held its own, yet almost no one in Canada ever heard about it. In this episode, host Jim Wilson speaks with founder and CEO Brad Sorenson about a journey that is as personal as it is professional. In 2013, Brad's 13-year-old son Adam was diagnosed with glioblastoma and given a year to live. Thirteen years later, Adam is still here, and Brad walks through the extraordinary series of events that shaped both his son's survival and the company he built. It is also a candid conversation about the realities of drug development in Canada and Brad's passionate call for the country to give patients the right to fight for their lives through compassionate access.

Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's. Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether. In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University. Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients. Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.

Based in Fredericton, New Brunswick, ResearchNB is the province's research funding agency. Think of the federal tri-councils CIHR, NSERC, and SSHRC combined into one and operating at a provincial level. In this episode, Jim Wilson speaks with CEO Candice Pollack about an organization that has moved well beyond the traditional role of a passive funder. Candice explains how ResearchNB now actively connects researchers with industry, government, and community to make sure good research does not simply end up as a paper on a shelf, but moves toward real impact whether through commercialization, policy change, or better patient care. Candice also makes a heartfelt case for New Brunswick as one of Canada's most underrated places for research and innovation, and why she believes the province's small, nimble approach is a strength rather than a limitation.

Node AI is a software as a medical device company based in Hamilton, Ontario using artificial intelligence to guide surgeons through endobronchial ultrasound, a critical procedure used to determine whether lung cancer has spread to the lymph nodes. Until now, surgeons performing it have essentially been navigating blind. In this episode, Jim Wilson speaks with co-founder and CEO Mackensey Bacon about a company that grew out of a surgeon's simple observation: if a phone can recognize a face, why can't AI identify a malignant lymph node? Mackensey explains how that idea became a company with four clinical trial sites across Canada and an FDA submission on track for the end of the year. Mackensey also reflects on the strength of Hamilton's life sciences ecosystem and what it takes to lead a startup alongside two of the best in their fields.

NovaSonix Healthcare is a medtech startup based in London, Ontario developing a portable attachment that converts any standard ultrasound machine into a real-time 3D scanner for musculoskeletal imaging. The goal is to give clinicians MRI-like image quality at the point of care, without the wait. In Canada, patients with musculoskeletal injuries and diseases currently wait an average of 89 days for a medically necessary MRI. In this episode, Jim Wilson speaks with co-founder and CEO Randa Mudathir about a company that began as a master's thesis project at Western University and found its footing after winning a pitch competition for bone and joint innovations. Randa walks through how a team of five co-founders came together, how clinical feedback pushed the company to broaden its focus beyond osteoarthritis detection, and why she believes the technology is ready for its next stage. With clinical pilots already underway, a pre-seed raise open, and Health Canada and FDA submissions planned for later this year, NovaSonix is moving fast.

Magellan Biomedical is a medical device company based in Toronto working on a problem that has been hiding in plain sight for almost a century. The fundamental tools used in cardiac catheterization have not meaningfully changed since 1929, and in some of the most critical procedures, conventional tools fail up to twenty percent of the time. In this episode, Jim Wilson speaks with co-founder and CEO Ali Tavallaei about a device called the CAT Pilot, which gives surgeons precise local control over the tip of a catheter during minimally invasive cardiovascular procedures. Where conventional tools achieve roughly a twelve percent success rate crossing arterial occlusions, the CAT Pilot achieves ninety-two percent. Ali walks through how the technology works, how the company spun out of Sunnybrook Research Institute, and why he believes an acquisition is a likely outcome once FDA approval is secured. This is a conversation about a long overdue disruption to a standard medical procedure, and a small Canadian team that decided to do something about it.

Dr. Lakshmi Krishnan is Vice President of Research (Life Sciences) at the National Research Council of Canada, one of the country's most influential science organizations in the country. The NRC connects industry, academia, and government to drive innovation and often is quietly behind-the-scenes helping steer some of the most significant advances in Canadian Life Sciences. In this episode, Jim Wilson speaks with Lakshmi about her journey that began in Chennai, India, wound through New Delhi, Edmonton, and Ottawa, and eventually lead to her becoming one of the most senior leaders in the Canadian Life Sciences community. Lakshmi shares insights about the mentors and unexpected moments that have helped shape her path, what it was like to lead the NRC's Life Sciences division through the COVID pandemic, and why she believes Canada is at a turning point in its ability to build and commercialize world-class science.

Today we reach into the archive to rebroadcast our interview with Maura Campbell, President & CEO of OBIO. Maura is one of the key leaders in Canada's life sciences community and it was a pleasure to speak with her. Listen in as she shares her thoughts on surviving a severe car accident, some of the obstacles she has faced as a woman working in life sciences, the disappointment of doing everything right but still having a company fail, and how keeping an open mind is important to success.

NerView Surgical is a medtech startup based in Hamilton, Ontario developing a handheld imaging device that gives surgeons the ability to visualize nerves in real time during surgery. It sounds like something that should already exist. It doesn't. The current standard of care is the naked eye. In this episode, Jim Wilson speaks with founder and CEO Mann Parikh about a company born out of a university course at McMaster, driven forward by a thousand cold emails to surgeons, and now supported by advisors at some of the most respected medical institutions in the world including Mayo Clinic, Stanford Medicine, and Harvard Medical School. Mann also opens up about the challenge of proving credibility as a student founder, the mentors who helped shape his thinking, and why he believes the best thing any young entrepreneur can do is stop waiting and start building.

Vasomune Therapeutics is a clinical stage biotech company that spun out of Sunnybrook Research Institute in Toronto. Their lead molecule targets vascular leak, a common underlying factor in some of the most serious conditions in medicine including sepsis, pneumonia, cerebral edema, and severe burns. In this episode, Jim Wilson speaks with the President and CEO if Vasomune, Brian Jahns, about a company that has made remarkable progress to date and secures nearly $10million USD in non-dilutive funding.  Brian makes a passionate case for Canadian self-reliance in life sciences... and asks Jim to share how the NGBi podcasts started.

This week we reach into our archive to replay one of our most popular interviews from 2024 with Brad Wouters, Executive Vice-President of Science and Research at University Health Network. Brad and I discuss his passion for medical biophysics, his accomplished academic career, what brought him to Europe, his return to Canada and the incredible research he and his team are doing at UHN.

Based in Mississauga, Ontario, Kare Chemical Technologies is a synthetic chemistry company working on something that sounds unlikely but could change how we treat chronic pain. By converting a byproduct of citrus orange peels into pharmaceutical grade cannabinoids, the company is developing non-psychoactive alternatives to opioids for patients dealing with long-term pain. In this episode, host Jim Wilson speaks with co-founder and COO Kareem Abdur-Rashid about a company that began with a family member's diagnosis, a father's decades of experience in organometallic chemistry, and a young scientist who signed up before fully realizing what he was getting into. Kareem walks through how the technology works, how the company bootstrapped its way to its first licensee, and why chronic pain remains one of the most underfunded areas in pharmaceutical development. This conversation is a candid look at early stage entrepreneurship from someone who is still in the thick of it, learning as he goes and building something that could genuinely help people get their lives back. We thank the NRC for supporting the NGBi podcasts. The National Research Council of Canada (NRC) is the Government of Canada's largest federal research and technology organization, focused on accelerating innovation, research, and development.

Claudia Krywiak is President and CEO of the Ontario Centre of Innovation which is a government-funded organization that helps small and medium-sized enterprises commercialize research by connecting industry, academic, and government partners to drive innovation across the province. In this episode, Jim Wilson speaks with Claudia Krywiak about her journey that began in a small town in Poland, wound through Dubai and Toronto, and eventually lead her to the heart of Ontario's innovation ecosystem. Jim speaks with Claudia talks about growing up between cultures, finding her footing in Canada, and how curiosity has been the common thread in her career. Claudia also shares her perspective on what is on the horizon in quantum computing and AI, why she believes the next two years will bring more technological change than the last decade, and why there has never been a better time to be an entrepreneur in Ontario.

In this episode of NGBiLab, Jim Wilson speaks with HygenX.AI co-founder and CTO Kris Rupay about a company that started in a garage during the pandemic and was originally founded to help restore confidence in air travel. What began as a UV disinfection robot for airplane aisles evolved into a potentially life-saving technology now being deployed in hospitals across North America. The team at HygenX.AI have developed an autonomous AI-driven robotic UV disinfection technology that is designed to make healthcare spaces safer, faster, and cleaner. Their robot, RAY, can disinfect a patient room in minutes rather than hours, while generating a real-time digital map of exactly what has been treated. Kris also talks about the challenges of pivoting from aviation to healthcare, the steep learning curve of building a medtech company without having a background in healthcare, and why he believes hospital-acquired infections are one of the most underreported public health crises in the world.

In the next episode of NGBideas Jim Wilson sits down with Gerald Prince who is Senior Director of GMP Manufacturing Gerald Prince at Bluerock Therapeutics.  Gerald's professional journey has wound through some of North America's largest food, consumer goods, and pharmaceutical companies and ultimately landed him at MaRS Discovery District in Toronto.  Gerald's story began in Stockton, California where his childhood home was unfortunately touched by gun violence but teachers and coaches believed in him before he believed in himself and their encouragement helped set Gerald on a career path defined by leadership, ambition and perseverence.  His journey eventually brought him to Canada and the forefront of cell and gene therapy where he and his team are helping change the future of medicine.  It is an inspiring story and we know you will enjoy learning about it.

Targa Biomedical is developing pharmacological solutions designed to improve the quality of cells, tissues, and organs for transplantation and regenerative medicine. Based in Montreal, Quebec, their technology has the potential to rescue damaged donor organs that would otherwise be discarded, making more transplants possible for patients in need. In this episode, host Jim Wilson speaks with co-founder and CEO Shant Der Sarkissian about how a chance observation in the lab, combined with a conversation with a cardiac surgeon next door, became the foundation for a company seven years in the making. Shant walks through the science behind conditioning damaged organs outside the body and why Targa believes it is first to market with this specific approach. Shant also reflects on the unique challenges of being an academic entrepreneur, and why he believes the confusion of having too many career options is actually a blessing in disguise.

SPEC Labs is a not-for-profit organization in Mississauga, Ontario that provides shared, ready-to-use wet lab space for life sciences startups in need of room to grow. Their all-inclusive model is designed to remove one of the biggest barriers facing Canadian biotech companies: access to affordable lab infrastructure. In this episode, host Jim Wilson speaks with founder and CEO Doris Qamar about how a frustrating gap in the Canadian market sparked an idea that took years to bring to life. What started as a search for scalable lab space for a small biotech company became a 20,000 square foot facility in Sheridan Research Park, now open and welcoming its first clients. Doris also makes a passionate case for why keeping innovation and intellectual property in Canada matters now more than ever.

Dr. Kullervo Hynynen is Vice President of Research and Innovation at Sunnybrook Health Sciences Centre in Toronto, Ontario, and a global leader in focused ultrasound technology. His decades of work have helped transform how the medical community approaches treatment for some of the most challenging neurological and oncological conditions. Join host Jim Wilson as he speaks with Dr. Hynynen about his remarkable journey that began on a small farm in rural Finland and lead to one of the most significant breakthroughs in the history of neuroscience. What started as a rejected NIH grant proposal became the foundation for a technology that can now open the blood-brain barrier non-invasively, potentially unlocking treatment for conditions like Alzheimer's and brain cancer. Kullervo also reflects on the personal losses that shaped his commitment to cancer research, and how a series of serendipitous career decisions, from Aberdeen to Arizona to Boston to Toronto, brought him to Sunnybrook. This conversation covers the stubbornness required to push through years of failed experiments, the challenge of commercializing science in Canada, and why Kullervo believes the next frontier is a focused ultrasound helmet that patients could one day use at home.

Cove Neurosciences is a precision neuroscience company in Toronto, Ontario that is focused on translating complex brain data into meaningful insights. Their analytics software helps researchers and pharmaceutical companies better understand human brain function without requiring specialized data science expertise. In this episode, host Jim Wilson speaks with co-founder and CEO Dr. Nardin Samuel about the company's unexpected beginnings inside a University of Toronto research lab. What started as a grant application to solve a data analysis problem became the foundation for a commercial software platform now targeting pharmaceutical companies and EEG device manufacturers. Nardin also opens up about the unique challenge of balancing life as a practicing neurology resident with running a startup, and how the team grew early on through university internship programs. This conversation covers the realities of the entrepreneurial rollercoaster, the mentorship that shaped Cove's early growth, and why Nardin believes that filtering signal from noise in brain data and in business is the key to staying focused on what matters most.